chartexchange

Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire Inc. | Nov 10, 2026 4:03 PM EST

52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893’s potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen

Read original article